These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29416779)

  • 1. The sphingosine kinase 2 inhibitor ABC294640 inhibits cervical carcinoma cell growth.
    Xu L; Jin L; Yang B; Wang L; Xia Z; Zhang Q; Xu J
    Oncotarget; 2018 Jan; 9(2):2384-2394. PubMed ID: 29416779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.
    Guan S; Liu YY; Yan T; Zhou J
    Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
    Zhou J; Chen J; Yu H
    Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
    Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W
    J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma.
    Ding X; Zhang Y; Huang T; Xu G; Peng C; Chen G; Kong B; Friess H; Shen S; Lv Y; Roberts LR; Wang L; Zou X
    Am J Cancer Res; 2019; 9(3):546-561. PubMed ID: 30949409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma.
    Shi W; Zhang S; Ma D; Yan D; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
    Front Oncol; 2020; 10():694. PubMed ID: 32670862
    [No Abstract]   [Full Text] [Related]  

  • 7. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
    Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
    Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sphingosine kinase 2 inhibitor ABC294640 displays anti-epithelial ovarian cancer activities in vitro and in vivo.
    Song K; Dai L; Long X; Cui X; Liu Y; Di W
    Onco Targets Ther; 2019; 12():4437-4449. PubMed ID: 31239712
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.
    White MD; Chan L; Antoon JW; Beckman BS
    Anticancer Res; 2013 Sep; 33(9):3573-9. PubMed ID: 24023282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.
    Sundaramoorthy P; Gasparetto C; Kang Y
    Cancer Med; 2018 Jul; 7(7):3257-3268. PubMed ID: 29761903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.
    Venant H; Rahmaniyan M; Jones EE; Lu P; Lilly MB; Garrett-Mayer E; Drake RR; Kraveka JM; Smith CD; Voelkel-Johnson C
    Mol Cancer Ther; 2015 Dec; 14(12):2744-52. PubMed ID: 26494858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SphK2/S1P Promotes Metastasis of Triple-Negative Breast Cancer Through the PAK1/LIMK1/Cofilin1 Signaling Pathway.
    Shi W; Ma D; Cao Y; Hu L; Liu S; Yan D; Zhang S; Zhang G; Wang Z; Wu J; Jiang C
    Front Mol Biosci; 2021; 8():598218. PubMed ID: 33968977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel sphingosine kinase inhibitor induces autophagy in tumor cells.
    Beljanski V; Knaak C; Smith CD
    J Pharmacol Exp Ther; 2010 May; 333(2):454-64. PubMed ID: 20179157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice.
    Poti F; Bot M; Costa S; Bergonzini V; Maines L; Varga G; Freise H; Robenek H; Simoni M; Nofer JR
    Thromb Haemost; 2012 Mar; 107(3):552-61. PubMed ID: 22234485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.
    French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD
    J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus-Infected Cell Autophagic Death and Represses Tumor Growth.
    Dai L; Bai A; Smith CD; Rodriguez PC; Yu F; Qin Z
    Mol Cancer Ther; 2017 Dec; 16(12):2724-2734. PubMed ID: 28939554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting SNAI1-Mediated Colorectal Cancer Chemoresistance and Stemness by Sphingosine Kinase 2 Inhibition.
    Janakiraman H; Gao Z; Zhu Y; Dong J; Becker SA; Janneh A; Ogretmen B; Camp ER
    World J Oncol; 2024 Oct; 15(5):744-757. PubMed ID: 39328328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.
    Schrecengost RS; Keller SN; Schiewer MJ; Knudsen KE; Smith CD
    Mol Cancer Res; 2015 Dec; 13(12):1591-601. PubMed ID: 26271487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells.
    McNaughton M; Pitman M; Pitson SM; Pyne NJ; Pyne S
    Oncotarget; 2016 Mar; 7(13):16663-75. PubMed ID: 26934645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sphingosine kinase 2 inhibitors ABC294640 and K145 elevate (dihydro)sphingosine 1-phosphate levels in various cells.
    Prell A; Wigger D; Huwiler A; Schumacher F; Kleuser B
    J Lipid Res; 2024 Oct; 65(10):100631. PubMed ID: 39182604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.